Dr. Trymore Magomana, MBA
DrPH • MBA • RAC-Devices®
Regulatory Affairs & Medical Device Executive | Global Health & Policy
I am a global regulatory affairs executive with over a decade of life-sciences experience directing medical-device strategy, compliance governance, and multi-market access across the U.S., EU, UK, LATAM, and APAC. Trained as a public-health scientist and systems thinker, I integrate regulatory rigor, health-policy insight, and responsible leadership to stabilize organizations, accelerate innovation, and strengthen patient outcomes worldwide.
Latest Insights
All insights →I write about regulatory governance and the systems that enable safe medical-device innovation across global markets. With training in sub-Saharan African public health systems, I also explore health policy, implementation, and institutional capacity-building across the region.
New perspectives, in one place.
New essays and professional reflections will appear here. Explore the profile, academic publications and creative works in the meantime.
The views expressed in these posts are my own and are provided for general informational purposes only. They do not represent the views of my employer or any affiliated organization and should not be interpreted as regulatory, legal, or business advice.
Academic Publications & Thesis
Creative Works (Novels)
Professional Profile
Dr. Trymore Magomana is a global regulatory affairs leader in medical devices with more than a decade of experience advancing disciplined governance, global health policy alignment, and medical device innovation across U.S., EU, UK, LATAM, and APAC markets. His work integrates complex regulatory frameworks with the practical realities of organizational leadership—ensuring that innovation, safety, and compliance advance together with clarity and integrity.
He specializes in transforming fragmented regulatory environments into coherent, audit-ready systems that support business continuity, market expansion, and responsible decision-making. His leadership reflects a commitment to evidence-based strategy, structured execution, and a global view of health outcomes.
Focus & Advocacy
Systems Leadership & Regulatory Governance
Rather than treating regulation as a constraint, Dr. Magomana advocates for a systems-thinking approach where compliance acts as the operating infrastructure for sustainable innovation. He emphasizes capability-building, the development of empowered teams, and the strategic use of frameworks such as FDA regulations, EU MDR, ISO 13485, MDSAP, and global vigilance systems to drive organizational resilience.
Public Health Integration & Global Policy Insight
Grounded in a Doctor of Public Health (DrPH), his perspective bridges the space between regulatory science and population-level health impact. He focuses on how disciplined execution—across clinical evidence, labeling governance, risk management, and lifecycle oversight—shapes patient safety and health system performance across diverse geographies.
Ethics, Transparency, & Responsible Leadership
His work is guided by a belief that scientific and regulatory progress are inseparable from ethical stewardship. He supports transparent decision-making, balanced risk evaluation, and governance models that maintain public trust in health technologies and the systems that regulate them.
The Path of Insight
Beginning in quality and regulatory engineering before advancing into senior regulatory affairs leadership roles at Ambu, CVRx, Abbott, and Wipro, Dr. Magomana has built a career grounded in disciplined execution across complex medical device environments. He has led U.S. and global market access strategies, EU MDR transitions, FDA submissions, clinical and regulatory evidence programs, and portfolio-level risk governance for multinational life-sciences organizations.
This website reflects the insights gathered across that journey—spanning regulatory operations, health authority engagement, post-market vigilance, digital regulatory systems, and global compliance architecture. It is a space where applied regulatory leadership, structured analysis, and long-term professional reflection come together.
Primary Purpose
“My purpose is to advance responsible leadership in regulatory affairs through disciplined execution, thoughtful inquiry, and contributions that strengthen the broader global discourse on regulatory science.”
Executive Leadership & Regulatory Impact
- Leads and mentors the site regulatory team, setting departmental direction, developing talent, and strengthening execution discipline across key programs
- Directs FDA and Notified Body engagement strategy for high-impact submissions, including 510(k), De Novo, and EU MDR programs
- Advises senior leadership on regulatory risk, product continuity, and market access priorities in support of enterprise growth
- Oversees post-market compliance programs spanning vigilance, PSUR, UDI, and labeling governance across global markets
- Directed regulatory strategy for PMA, IDE, supplements, and clinical study activities supporting Class III implantable device programs
- Led cross-functional regulatory support for clinical trials, including FDA engagement, evidence strategy, and alignment with study execution priorities
- Partnered with FDA, CROs, and Notified Bodies to advance approvals, manage regulatory risk, and support global market access objectives
- Contributed to EU MDR readiness, post-market compliance, and cybersecurity-related regulatory activities for connected implantable technologies
- Advised senior leadership and mentored regulatory staff in a fast-moving growth environment where regulatory execution was critical to scale and continuity
- Led EU MDR transition and Technical Documentation remediation activities for vascular and cardiac medical device portfolios
- Directed regulatory workstreams involving labeling, CER, CEP, PSUR, and design/change management to maintain compliance across evolving global requirements
- Executed global submission and lifecycle strategies to support product continuity, market access, and portfolio sustainability
- Partnered cross-functionally with quality, clinical, engineering, and commercial stakeholders to align regulatory priorities with enterprise objectives
- Contributed to a high-performance regulatory environment where precision, scale, and execution discipline were essential across a major multinational device manufacturer
- Led and supported regulatory strategy across Class II and Class III device portfolios, including U.S. 510(k) activity, PMA-related workstreams, international submissions, and market continuity planning
- Directed and contributed to large-scale EU MDR transition and remediation programs involving Technical Documentation, CER alignment, risk management integration, labeling updates, and portfolio prioritization
- Worked closely with quality, engineering, clinical, and manufacturing teams to resolve compliance gaps, strengthen change control, and align regulatory deliverables with operational realities
- Supported quality-system and post-market workstreams involving CAPA, complaint handling, risk files, design changes, and broader remediation initiatives in regulated manufacturing environments
- Helped organizations respond to complex documentation, product, and quality challenges where regulatory clarity was essential to inspection readiness, audit defensibility, and commercial continuity
- Built fluency across a wide range of device domains, including surgical systems, electrophysiology and cardiac technologies, blood-processing platforms, capital equipment, and general medical devices
- Served as a trusted consulting partner to major medtech manufacturers, bringing structure, execution discipline, and cross-portfolio perspective to high-priority regulatory and quality initiatives
- Johnson & Johnson (Ethicon & Biosense Webster): Supported major regulatory and remediation programs across surgical and electrophysiology/cardiovascular device environments
- Integra LifeSciences: Contributed to remediation and submission activities across complex neurosurgical and medical technology portfolios
- Terumo BCT: Supported blood-processing and related system remediation in a highly regulated global environment
- Baxter Healthcare: Prepared U.S. and international submission materials and supported broader regulatory lifecycle activity
- Candela Medical: Supported 510(k) development, labeling compliance, and associated regulatory operations workstreams
- Supported device testing, standards evaluation, and conformity assessment activities across electrical and product safety domains
- Applied risk-based thinking aligned with ISO 14971 to help assess product safety and compliance considerations
- Contributed to technical documentation review and evidence development supporting regulatory and quality expectations
- Built early expertise in the intersection of product safety, quality assurance, and regulatory compliance within medical device environments
Strategic Leadership & Global Governance
Directing enterprise-wide regulatory infrastructure for Class II and III medical technologies.
Regulatory Affairs & Market Entry
- Directing 510(k), PMA, and De Novo pathways to secure U.S. market access.
- Strategic oversight of EU MDR Technical Documentation and UKCA registrations.
- Executive management of market access strategy for APAC, LATAM, and Canada.
- Applying IEC 62304 and ISO 14971 to software-enabled connected devices.
- Directing cybersecurity and privacy-by-design regulatory requirements.
- Strategy for AI/ML-based technologies and cloud-hosted medical platforms.
- Oversight of CER/CEP pipelines and SSCP clinical deliverable authoring.
- Strategic management of Post-Market Clinical Follow-Up (PMCF) plans.
- Securing IDE and clinical trial protocol approvals with health authorities.
- Primary interface for FDA, Notified Body, and global agency negotiations.
- Directing deficiency response strategy to de-risk market approval timelines.
- Leading technical documentation defense during complex enterprise audits.
- Building and mentoring high-impact regulatory and clinical affairs teams.
- Strategic oversight of GUDID, EUDAMED, and global UDI governance.
- Directing vigilance reporting and risk-based post-market surveillance.
- Strategic advisor to leadership on M&A, NPD, and portfolio expansion.
- Implementing system-wide MDD/IVDD to MDR/IVDR transitions.
- Driving cross-functional alignment between R&D, Quality, and Marketing.
Health Policy & Systems Thinking
- Bridging regulatory science with population-level health impact.
- Expertise in institutional capacity-building in sub-Saharan markets.
- Strategic analysis of policy effects on healthcare infrastructure access.
- Applying ethical stewardship to global clinical trial governance.
- Developing defensible rationales for complex bioethical challenges.
- Aligning product safety governance with international patient trust.
- Translating clinical trial requirements into device regulatory outcomes.
- Aligning drug and device controls for combination product strategies.
- Driving enterprise-wide transformation through structured regulatory data.
Selected Projects
Selected projects reflect the breadth of Dr. Magomana’s leadership across regulatory strategy, market access, remediation, and lifecycle governance. The examples below are representative of the types of work he has led or supported across global medical device organizations and consulting engagements.
Led and supported regulatory strategy for U.S. market access across Class II and Class III medical devices, including 510(k), PMA, IDE, and supplement pathways. Worked cross-functionally with engineering, clinical, quality, and leadership teams to align submission planning with business objectives and regulatory expectations.
Directed and contributed to MDR transition programs involving technical documentation upgrades, CER/CEP alignment, risk management integration, and remediation of legacy files. Supported organizations navigating capacity constraints, notified body expectations, and portfolio prioritization decisions.
Supported design and strengthening of post-market compliance frameworks, including complaint handling, vigilance reporting, PMS, PMCF, and labeling governance. Helped teams translate regulatory obligations into workable business processes and sustainable oversight structures.
Managed and advised on multi-market regulatory pathways spanning the U.S., EU, UK, LATAM, APAC, and Canada. Supported market expansion, renewals, change management, product updates, and portfolio continuity through disciplined lifecycle planning.
Led and supported operational programs involving UDI/GUDID governance, labeling review, submission documentation, and cross-functional change control. Focused on creating scalable, audit-ready systems that improved regulatory consistency across product portfolios.
Advised global life-sciences and medtech clients on regulatory strategy, remediation, clinical evidence, and quality-system alignment. Engagements included workstreams across cardiovascular, surgical, vascular, blood-processing, and general medical device categories.
Speaking & Media
Dr. Trymore Magomana is available for speaking engagements, panel discussions, executive commentary, and expert interviews on medical device regulatory affairs, global health governance, and health policy in Southern Africa. His perspective integrates frontline regulatory leadership in the U.S. and global medtech markets with academic training in public health, ethics, and systems thinking.
Focus Areas
- Medical device regulatory strategy, including FDA, EU MDR, and global market access
- Regulatory leadership, governance, and quality-system integration
- Post-market compliance, vigilance, labeling, and lifecycle management
- SaMD, digital health, and the future of device oversight
- Global health systems, access, and implementation challenges in Southern Africa
- Health policy, institutional capacity, and public-sector governance in Zimbabwe and the region
Current Participation
Advisory & Service
Dr. Trymore Magomana is interested in contributing his experience to boards, advisory groups, nonprofit initiatives, academic programs, and mission-driven organizations where regulatory insight, governance discipline, and global health perspective can add value.
Areas of Interest
- Health and public health nonprofits
- Medical device and life-sciences advisory boards
- Academic and student mentorship initiatives
- Zimbabwean and Southern African development, health, and education causes
- Governance, ethics, and policy-focused organizations
- Community and institution-building initiatives with long-term social value
How He Can Help
He is available to support organizations through advisory participation, board service, mentoring, governance input, strategic review, and selected volunteer efforts aligned with health systems, regulation, education, and responsible leadership.
Education & Executive Credentials
A multidisciplinary foundation spanning regulatory science, public health, ethics, and international strategy.